Anthrax Market Pipeline Global Review Research Report for H2 2015

USA - English

• India - English

PUNE, India, March 18, 2016 /PRNewswire/ --

The "Anthrax - Pipeline Review, H2 2015" market research report provides an overview of the Anthrax's therapeutic pipeline and helps enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Company Profiles discussed in this report includes Aduro BioTech, Inc., Altimmune, Inc., Aphios Corporation, Aradigm Corporation, Bavarian Nordic A/S, Bristol-Myers Squibb Company, Cellceutix Corporation, ContraFect Corporation, Dynavax Technologies Corporation, ,Elusys Therapeutics, Inc. Emergent BioSolutions Inc., Green Cross Corporation, Grifols, S.A., Hawaii Biotech, Inc., iBio, Inc., Innovative Biologics, Inc., Microbiotix, Inc., NanoBio Corporation, Oragenics, Inc., PaxVax, Pfenex Inc., PharmAthene, Inc., Protein Potential, LLC, ProThera Biologics, LLC., PsiOxus Therapeutics Limited, Soligenix, Inc., Syntiron LLC , Tetraphase Pharmaceuticals Inc., United Therapeutics Corporation and VLP Biotech, Inc.

Complete report on H2 2015 pipeline review of Anthrax with 53 market data tables and 15 figures, spread across 160 pages is available at http://www.reportsnreports.com/reports/432806-anthrax-pipeline-review-h2-2015.html   

Drugs Profiles discussed in this report includes anthrax + plague vaccine, anthrax vaccine - Drug Profile, anthrax vaccine next generation, anthrax virus like particle vaccine, ARD-3100, AV-7909, CF-306, CF-307, CF-308, ciprofloxacin hydrochloride, DPX-Anthrax, DV-230, Epimerox, GC-1109, GREANX, Human Antibody Based Vaccines, KKL-35, Marinus, MDX-1303, Monoclonal Antibody for Respiratory Anthrax, Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax, MU-1140, MVA-BN Anthrax, obiltoxaximab, PBI-220, Peptides to Disrupt Cell Membrane for Infectious Diseases, PMX-0196, PMX-0231, PMX-0243, PMX-225, PreviThrax, Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis, Px-563L, RC-100b, RiVax + SGX-204, Second Generation Px-563L, SGX-204, Small Molecule to Inhibit Anthrax Toxin and Alpha Hemolysin for Anthrax and Staphylococcal aureus Pneumonia, Small Molecule to Inhibit DNA Helicase for Infectious Diseases, Small Molecule to Inhibit Enoyl-Reductase for Bacillus Anthracis and Francisella Tularensis Infections, Small Molecules for Bacterial Infections, Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax, Small Molecules to Inhibit Lethal Factor for Anthrax, Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis, Synthetic Peptides for Bacterial Infections and TP-271.

Order a Purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=432806  (This is a premium report priced at US$2000 for a single user License.)

This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Anthrax. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and also key players involved in the therapeutics development for Anthrax and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects. A review of the Anthrax products under development by companies and universities/research institutes based on information derived from company and industry-specific sources, pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Anthrax pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.

Another newly published market research report titled on Staphylococcus aureus Infections - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Staphylococcus aureus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Staphylococcus aureus Infections and special features on late-stage and discontinued projects. Staphylococcus aureus Infections Pipeline market research report of 538 pages is available at http://www.reportsnreports.com/reports/468292-staphylococcus-aureus-infections-pipeline-review-h2-2015.html   

Explore more reports on Pharmaceuticals

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml = 

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
[email protected]

SOURCE ReportsnReports